Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 etrasimod induction study in moderate to severe active ulcerative colitis
MOH_2019-12-02_008532Phase 3Not yet recruiting
- Sponsor
- Arena Pharmaceuticals, Inc.
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Etrasimod with Placebo (2 arms). Primary endpoint: Clinical remission at 12 weeks. Planned start Jul 2019; status: not yet recruiting.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on MOH_2019-12-02_008532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-12-02_008532.